Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021040570 - MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES

Publication Number WO/2021/040570
Publication Date 04.03.2021
International Application No. PCT/RU2020/050193
International Filing Date 19.08.2020
IPC
A61K 41/00 2020.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
41Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61P 31/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61K 31/43
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/7036
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
7036having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Applicants
  • EPSHTEIN, Oleg Iliich [RU]/[RU]
Inventors
  • EPSHTEIN, Oleg Iliich
  • PUSHKAR, Dmitry Yurievich
Agents
  • MUKHINA, Anna Konstantinovna
Priority Data
201912718529.08.2019RU
201912718629.08.2019RU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES
(FR) MÉDICAMENT ET MÉTHODE DE TRAITEMENT DE MALADIES INFECTIEUSES
Abstract
(EN)
This invention relates to the field of medicine, particularly to a medicament for treating bacterial infections, which presents a technology-processed product resulting from multiple serial dilutions of the stock substances of antibodies to HLA-DRB1 and antibodies to β2-microglobulin, and to a combination of the claimed medicament with antibiotic, to a method of treating bacterial infections, a method of reducing bacterial resistance to antibiotic therapy and a method of enhancing antibiotic efficacy. Besides, this invention relates to a medicament for treating infectious diseases, which exerts antibacterial and antiviral effects and presents a technology-processed product resulting from multiple serial dilutions of the stock substances of a) antibodies to HLA-DRB1, b) antibodies to β2-MG, c) antibodies to IFN-γ and d) antibodies to CD4. This invention ensures an effective treatment of infectious diseases, decreases resistance to antibiotics, enhances the therapeutic efficacy of antibiotics, including efficacy against resistant bacteria, and reduces effective doses of antibiotics.
(FR)
La présente invention relève du domaine de la médecine, et concerne en particulier un médicament destiné au traitement d'infections bactériennes, qui se présente comme étant un produit traité par technologie résultant de plusieurs dilutions en série de substances mères d'anticorps dirigés contre HLA-DRB1 et d'anticorps dirigés contre β2-microglobuline, et une combinaison médicament-antibiotique, une méthode de traitement d'infections bactériennes, une méthode permettant de réduire la résistance bactérienne à une thérapie à base d'antibiotique et une méthode d'amélioration de l'efficacité antibiotique. En outre, la présente invention concerne un médicament destiné au traitement de maladies infectieuses, qui exerce des effets antibactériens et antiviraux et qui se présente comme étant un produit traité par technologie résultant de plusieurs dilutions en série de substances mères a) d'anticorps dirigés contre HLA-DRB1, b) d'anticorps dirigés contre β2-MG, c) d'anticorps dirigés contre IFN-γ et d) d'anticorps dirigés contre CD4. La présente invention offre un traitement efficace contre des maladies infectieuses, diminue la résistance aux antibiotiques, améliore l'efficacité thérapeutique des antibiotiques, notamment l'efficacité contre les bactéries résistantes, et réduit les doses efficaces d'antibiotiques.
Latest bibliographic data on file with the International Bureau